Apellis Pharmaceuticals, Inc.
APLS
Helyezés a részvények között
#3335
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Részvényárfolyam
$41.03
Utolsó szinkronizálás: 2026-05-15
Piaci kapitalizáció
$5.25B
Változás (1 nap)
0.00%
Változás (1 év)
44.93%
Ország
US
Kereskedés Apellis Pharmaceuticals, Inc. (APLS)
Kategória
Healthcare
Apellis Pharmaceuticals, Inc. (APLS) kintlévő részvényeinek száma
Kintlévő részvények száma ekkor: March 2026: 0.00
Apellis Pharmaceuticals, Inc. legfrissebb pénzügyi jelentései és részvényára alapján a cég jelenlegi kintlévő részvényeinek száma 0.00. December 2023 végén a vállalatnak 118.68M kintlévő részvénye volt. A kintlévő részvények száma általában részvényfelosztásokkal és visszavásárlásokkal változik.
Apellis Pharmaceuticals, Inc. (APLS) kintlévő részvényeinek története 2013 és 2026 között
Kintlévő részvények az év végén
| Év | Kintlévő részvények | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | 123.91M | 4.40% |
| 2023 | 118.68M | 11.84% |
| 2022 | 106.11M | 25.70% |
| 2021 | 84.42M | 12.32% |
| 2020 | 75.16M | 20.78% |
| 2019 | 62.23M | 14.40% |
| 2018 | 54.40M | 58.94% |
| 2017 | 34.22M | 89.15% |
| 2016 | 18.09M | 0.00% |
| 2015 | 18.09M | 0.00% |
| 2014 | 18.09M | 294.79% |
| 2013 | 4.58M | 0.00% |
Kintlévő részvények hasonló cégek vagy versenytársak esetén
| Vállalat | Kintlévő részvények | Különbség | Ország |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| - | - |
CH
|
|
| 62.19M | - |
NL
|
